GlassScriptPhysician profile
Nicholle Walton
NPI 1740998731
$1,664.84
in general payments reported to CMS, 2019-2025
19 companies · $217 in 2025
The $217 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $694 · 2024: $753 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,633 · Education: $31.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,633.04 |
| Education | $31.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $263.25 | 2023-2024 | Tavneos |
| Astrazeneca Pharmaceuticals LP | $260.11 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $200.31 | 2023-2024 | Jynarque |
| Ardelyx, INC. | $181.55 | 2023-2024 | Xphozah 30 Mg, Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $138.47 | 2023-2024 | |
| Horizon Therapeutics Plc | $124.99 | 2023 | Krystexxa |
| Travere Therapeutics, INC. | $94.29 | 2023-2024 | |
| Aurinia Pharma U.S., INC. | $70.07 | 2023-2024 | Lupkynis |
| Calliditas Therapeutics US INC. | $56.74 | 2023-2024 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $54.25 | 2023-2024 | Rayaldee |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $35.68 | 2023 | Jynarque |
| Akebia Therapeutics INC | $29.84 | 2024 | Vafseo, Auryxia |
| Dexcom, INC. | $29.73 | 2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $25.08 | 2024 | |
| Abbvie INC. | $24.10 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $23.06 | 2024 | Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.41 | 2024 | Jardiance |
| Pfizer INC. | $17.15 | 2025 | |
| Daiichi Sankyo INC. | $14.76 | 2024 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholle Walton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.